127 related articles for article (PubMed ID: 8404928)
1. Breakpoint determination: rufloxacin.
Eur J Clin Microbiol Infect Dis; 1993 Jul; 12(7):574-5. PubMed ID: 8404928
[No Abstract] [Full Text] [Related]
2. ESGAB breakpoint determination: temafloxacin.
Phillips I; Acar J; Baquero F; Bergan T; Forsgren A; Wiedemann B
Eur J Clin Microbiol Infect Dis; 1991 Nov; 10(11):991-2. PubMed ID: 1665417
[No Abstract] [Full Text] [Related]
3. [Pharmacodynamic and pharmacokinetic approaches to optimization of lomefloxacin].
Iakovlev SV
Antibiot Khimioter; 1998; 43(10):42-5. PubMed ID: 9825110
[No Abstract] [Full Text] [Related]
4. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
[TBL] [Abstract][Full Text] [Related]
5. Two new fluoroquinolones.
Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502
[No Abstract] [Full Text] [Related]
6. Sparfloxacin and other new fluoroquinolones.
Richard P; Gutmann L
J Antimicrob Chemother; 1992 Dec; 30(6):739-44. PubMed ID: 1337749
[No Abstract] [Full Text] [Related]
7. Comparative in-vitro activity of rufloxacin with five other antimicrobial agents against bacterial enteric pathogens.
Soriano F; Fernández-Roblas R; López JC; García-Corbeira P; Aguilar L
J Antimicrob Chemother; 1994 Jul; 34(1):157-60. PubMed ID: 7961202
[No Abstract] [Full Text] [Related]
8. Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.
Mattina R; Cocuzza CE; Cesana M
Infection; 1993; 21(2):106-11. PubMed ID: 8387963
[TBL] [Abstract][Full Text] [Related]
9. [The importance of fluoroquinolones in treating pneumonia in the elderly].
Belousov IuB; Efremenkova OV; Sokolov AV; Tishenkova IF
Antibiot Khimioter; 1999; 44(12):23-6. PubMed ID: 10687030
[No Abstract] [Full Text] [Related]
10. Comparison of rufloxacin and norfloxacin effects on faecal flora.
Marco F; Giménez MJ; Jiménez de Anta MT; Marcos MA; Salvá P; Aguilar L
J Antimicrob Chemother; 1995 Jun; 35(6):895-901. PubMed ID: 7559202
[TBL] [Abstract][Full Text] [Related]
11. In vitro antimicrobial activity of lomefloxacin against staphylococci, enterococci, and Enterobacteriaceae.
Rossolini GM; Valentini S; Vaiani G; Satta G
J Chemother; 1989 Jul; 1(4 Suppl):173-6. PubMed ID: 16312356
[No Abstract] [Full Text] [Related]
12. In vitro activity of sparfloxacin against selected enterobacteriaceae and pseudomonaceae including Ps. pseudomallei (melioidosis).
Siristonpun Y; Rojnapisarnvong V; Srimuang S; Tanphaichitra D
J Chemother; 1995 Nov; 7 Suppl 4():54-5. PubMed ID: 8904106
[No Abstract] [Full Text] [Related]
13. [Lemofloxacin: antimicrobial ability and clinico-pharmacokinetic basis for use in urogenital infections].
Iakovlev SV
Urologiia; 2002; (1):11-4. PubMed ID: 11877963
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis.
Klietmann W; Cesana M; Rondel RK; Focht J
Antimicrob Agents Chemother; 1993 Nov; 37(11):2298-306. PubMed ID: 8285609
[TBL] [Abstract][Full Text] [Related]
15. Levofloxacin and sparfloxacin: new quinolone antibiotics.
Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
[TBL] [Abstract][Full Text] [Related]
16. In-vitro activity of OPC-17116 against bacterial enteric pathogens.
Arduino RC; Frosolono M; Murray BE
J Antimicrob Chemother; 1994 Sep; 34(3):403-7. PubMed ID: 7829414
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics of rufloxacin once daily in patients with lower respiratory tract infections.
Rimoldi R; Fioretti M; Albrici A; Imbimbo BP
Infection; 1992; 20(2):89-93. PubMed ID: 1316313
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of the fluoroquinolones.
Scully BE
Urology; 1990 Jan; 35(1 Suppl):8-10. PubMed ID: 2404373
[No Abstract] [Full Text] [Related]
19. Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.
Qadri SM; Ueno Y; Postle G; Tullo D; San Pedro J
Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):372-7. PubMed ID: 8394816
[TBL] [Abstract][Full Text] [Related]
20. Disk susceptibility testing for rufloxacin.
Andrews JM; Wise R
Eur J Clin Microbiol Infect Dis; 1993 Dec; 12(12):974-6. PubMed ID: 8187800
[No Abstract] [Full Text] [Related]
[Next] [New Search]
